Literature DB >> 28509143

Anaphylactoid reaction to immunoadsorptive membrane in a patient with myasthenia gravis.

Yoshihiko Kanno1, Shigeaki Suzuki2, Tadashi Yoshida3, Yugaku Date2, Norihiro Suzuki2, Matsuhiko Hayashi3.   

Abstract

Extracorporeal adsorption therapy has been carried out clinically in cases of myasthenia gravis (MG) since the 1980s without any major complications. Despite a lack of clinical evidence, it has been accepted as a potential therapy for steroid-resistant patients in many institutes. Recently, we experienced a case of MG with an anaphylactoid reaction during extracorporeal immunoadsorption therapy. A 64 year old women with MG showed an anaphylactoid reaction immediately after the initiation of adsorption therapy using a polyvinylalcohol gel column. It is therefore important to bear in mind that extracorporeal adsorption therapy could trigger an anaphylactoid reaction, which may induce a MG crisis.

Entities:  

Keywords:  Crisis; Myasthenia gravis; Shock; TR350

Year:  2011        PMID: 28509143      PMCID: PMC5387791          DOI: 10.1007/s13730-011-0001-2

Source DB:  PubMed          Journal:  CEN Case Rep        ISSN: 2192-4449


  8 in total

Review 1.  Diagnosis and management of autoimmune myasthenia gravis.

Authors:  Corrado Angelini
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

Review 2.  Evidence-based guideline update: Plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Authors:  I Cortese; V Chaudhry; Y T So; F Cantor; D R Cornblath; A Rae-Grant
Journal:  Neurology       Date:  2011-01-18       Impact factor: 9.910

3.  Successful removal of pathogenic autoantibodies in pemphigus by immunoadsorption with a tryptophan-linked polyvinylalcohol adsorber.

Authors:  M Lüftl; A Stauber; A Mainka; R Klingel; G Schuler; M Hertl
Journal:  Br J Dermatol       Date:  2003-09       Impact factor: 9.302

4.  Future therapeutic strategies in autoimmune myasthenia gravis.

Authors:  Loukia Psaridi-Linardaki; Avgi Mamalaki; Socrates J Tzartos
Journal:  Ann N Y Acad Sci       Date:  2003-09       Impact factor: 5.691

5.  Tryptophan-immobilized column adsorbs immunoglobulin G anti-GQ1b antibody from Fisher's syndrome: A new approach to treatment.

Authors:  N Yuki
Journal:  Neurology       Date:  1996-06       Impact factor: 9.910

6.  Treatment of myasthenia gravis by immunoadsorption of plasma.

Authors:  D Grob; D Simpson; H Mitsumoto; B Hoch; F Mokhtarian; A Bender; M Greenberg; A Koo; S Nakayama
Journal:  Neurology       Date:  1995-02       Impact factor: 9.910

7.  Classification of myasthenia gravis based on autoantibody status.

Authors:  Shigeaki Suzuki; Kimiaki Utsugisawa; Yuriko Nagane; Takashi Satoh; Yasuo Terayama; Norihiro Suzuki; Masataka Kuwana
Journal:  Arch Neurol       Date:  2007-08

Review 8.  Heparin-induced anaphylactic and anaphylactoid reactions: two distinct but overlapping syndromes.

Authors:  Theodore E Warkentin; Andreas Greinacher
Journal:  Expert Opin Drug Saf       Date:  2009-03       Impact factor: 4.250

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.